Astellas Pharma and Eko Health have entered into a License & Supply Agreement to globally supply and license Eko's latest digital stethoscope, the CORE 500™, along with AI-powered cardiovascular disease detection software.
Astellas plans to integrate Eko's technology with Welldoc's cardiometabolic digital therapeutic capabilities to create a non-invasive device-DTx solution called Z1608 for heart failure patients. The aim is to seek FDA clearance for Z1608 and evaluate its effectiveness in remote monitoring and reducing acute decompensation events.
The partnership also provides educational content on heart failure from the American Heart Association (AHA) as part of Z1608.
The prevalence of heart failure is increasing, and the collaboration aims to address the unmet medical need for a portable and user-friendly digital solution for heart failure management.
Click here to read the original news story.